Affinage

PRMT2

Protein arginine N-methyltransferase 2 · UniProt P55345

Length
433 aa
Mass
49.0 kDa
Annotated
2026-06-10
33 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRMT2 is a type I protein arginine methyltransferase that couples substrate methylation to transcriptional and signaling control, deploying an N-terminal protein-interaction module to recruit substrates and partners while its methyltransferase core deposits asymmetric dimethylarginine (PMID:29689199, PMID:30382083). In the nucleus, its principal chromatin activity is asymmetric dimethylation of histone H3 at arginine 8 (H3R8me2a), which it installs at gene promoters and enhancers to activate oncogenic and stimulus-responsive transcriptional programs, including cell-cycle, Bcl2, WNT5A, and hypoxia-induced genes across glioblastoma, hepatocellular carcinoma, and renal cell carcinoma (PMID:30382083, PMID:32574605, PMID:37173306, PMID:38341123). PRMT2 also methylates a spectrum of non-histone substrates with distinct functional outcomes: it methylates BRD4 to promote its chromatin recruitment for transcription and DNA repair (PMID:36475791), TLR4 and IRF3 to drive IRF3 dimerization and IFN-β production (PMID:34583098), HIV-1 Tat at R52 to enforce nucleolar sequestration and viral latency (PMID:37949879), β-catenin to trigger its proteasomal degradation and downstream GPX4 repression (PMID:38430350), and the actin nucleator Cobl, a modification required for Cobl actin-binding activity in neuronal dendritogenesis (PMID:29689199). Independent of, or in concert with, its catalytic activity PRMT2 acts as a co-activator for nuclear hormone receptors AR and ERα and as an RB-dependent repressor of E2F1 transcriptional activity, with PRMT2-null cells showing elevated E2F activity and accelerated S-phase entry (PMID:17587566, PMID:22093364, PMID:16616919). Its protein-interaction domain engages partners including the hnRNP E1B-AP5, the splicing factor SAM68, and Cobl, linking PRMT2 to RGG-box methylation, BCL-X alternative splicing, and cytoskeletal regulation (PMID:11513728, PMID:28057797, PMID:29689199). PRMT2 function is itself tuned by post-translational regulation—CDK9 phosphorylation at Ser12 drives its condensation into transcriptional condensates required for H3R8me2a activity, and PADI4-mediated citrullination at R312 stabilizes the protein (PMID:40926175, PMID:40078091).

Mechanistic history

Synthesis pass · year-by-year structured walk · 22 steps
  1. 1998 Medium

    Established PRMT2 as a candidate arginine methyltransferase, placing it within a family whose catalytic conservation was demonstrated for its paralog.

    Evidence Sequence analysis with yeast complementation and in vitro methyltransferase assay of the paralog HRMT1L2

    PMID:9545638

    Open questions at the time
    • PRMT2 itself assigned by homology, not direct enzymatic assay
    • no substrate identified at this stage
  2. 2001 Medium

    Showed PRMT2's N-terminal domain mediates partner binding, identifying the first interactor and a candidate nuclear methylation substrate.

    Evidence Yeast two-hybrid, immunofluorescence co-localization and domain-deletion analysis with the hnRNP E1B-AP5

    PMID:11513728

    Open questions at the time
    • direct in vitro methylation of E1B-AP5 by PRMT2 not demonstrated
    • functional consequence of methylation unknown
  3. 2006 High

    Defined a cell-cycle role by showing PRMT2 represses E2F1 in an RB-dependent manner, the first genetic loss-of-function phenotype.

    Evidence Co-IP, reporter assays, PRMT2-knockout MEFs with cell-cycle analysis and vascular injury model

    PMID:16616919

    Open questions at the time
    • whether repression requires catalytic methylation not resolved
    • no direct chromatin substrate at E2F target genes identified
  4. 2007 Medium

    Identified PRMT2 as a nuclear hormone receptor co-activator with catalytic activity required and ligand-dependent nuclear co-translocation.

    Evidence Yeast two-hybrid, luciferase reporter, immunofluorescence and methyltransferase-inhibitor treatment with androgen receptor

    PMID:17587566

    Open questions at the time
    • substrate methylated during coactivation not identified
    • single lab
  5. 2011 Medium

    Extended coactivator function to ERα and connected PRMT2 to E2F1-driven proliferation, while showing splice variants partition to distinct compartments.

    Evidence Confocal microscopy, GST pulldown, Co-IP, reporter assays and siRNA in ERα systems

    PMID:22093364

    Open questions at the time
    • catalytic requirement for ERα coactivation not tested
    • functional roles of individual splice variants incompletely separated
  6. 2011 Medium

    Linked PRMT2 to innate immune signaling in vivo through control of NF-κB nuclear accumulation.

    Evidence Prmt2 mouse knockout/monosomy model, cytokine measurement and NF-κB nuclear fractionation

    PMID:21957146

    Open questions at the time
    • molecular mechanism connecting PRMT2 to NF-κB not defined
    • no substrate identified
  7. 2015 Medium

    Placed PRMT2 in macrophage lipid handling via LXR-dependent ABCA1 expression and cholesterol efflux.

    Evidence Prmt2-knockout BMDMs with cholesterol efflux assay and gene expression analysis

    PMID:26288135

    Open questions at the time
    • mechanism of PRMT2 action on LXR/ABCA1 not resolved
    • catalytic dependence untested
  8. 2017 Medium

    Revealed an SH3-domain-mediated link to alternative splicing through SAM68 and BCL-X isoform control.

    Evidence SH3-domain proteomics, Co-IP and RT-PCR BCL-X isoform analysis

    PMID:28057797

    Open questions at the time
    • whether SAM68 is methylated by PRMT2 not established
    • single lab
  9. 2018 High

    Identified H3R8me2a as PRMT2's chromatin mark and tied its catalytic activity to oncogenic transcription, the central nuclear mechanism.

    Evidence ChIP-seq, knockdown, catalytic-mutant expression and tumor models in glioblastoma

    PMID:30382083

    Open questions at the time
    • recruitment mechanism of PRMT2 to specific promoters not defined
    • reader of H3R8me2a not identified here
  10. 2018 High

    Demonstrated a direct non-histone substrate (Cobl) with reconstituted methylation controlling actin nucleation and dendritogenesis, requiring both catalytic and SH3 domains.

    Evidence In vitro and cellular reconstitution, in vitro methylation, actin-binding assay and neuronal gain/loss-of-function

    PMID:29689199

    Open questions at the time
    • methylated arginine residues on Cobl not enumerated in summary
    • in vivo neuronal circuit consequences beyond arborization untested
  11. 2020 Medium

    Connected H3R8me2a to chromatin accessibility, showing it opens the Bcl2 promoter for STAT3 binding.

    Evidence ChIP, catalytic-mutant and MS023 inhibitor treatment with apoptosis/proliferation assays in HCC

    PMID:32574605

    Open questions at the time
    • direct biochemical link between H3R8me2a and STAT3 recruitment not shown
    • single lab
  12. 2021 Medium

    Mapped PRMT2 methylation of TLR4 and IRF3 to defined arginines, establishing a methylation-driven IFN-β signaling cascade.

    Evidence Co-IP, in vitro methylation, active-site and substrate mutagenesis, nuclear fractionation and IFN-β reporter assays

    PMID:34583098

    Open questions at the time
    • stoichiometry and in vivo relevance of these methylations untested
    • single lab
  13. 2021 Medium

    Showed H3R8me2a can act repressively, silencing SOCS3 to stabilize TRAF5 and activate NF-κB/MAPK in colitis.

    Evidence ChIP, in vivo lentiviral overexpression/knockdown and DSS colitis model

    PMID:34599829

    Open questions at the time
    • mechanism of activating versus repressive H3R8me2a outcomes unresolved
    • single lab
  14. 2022 High

    Defined BRD4 as a methylation substrate, linking PRMT2 to chromatin reader recruitment, transcription, and DNA-damage repair with therapeutic implications.

    Evidence In vitro methylation with site-mapped mutagenesis, ChIP, xenograft and drug-sensitivity assays

    PMID:36475791

    Open questions at the time
    • relative contribution of PRMT2 versus PRMT4 to BRD4 methylation not partitioned
    • signal triggering DNA-damage-induced methylation undefined
  15. 2023 High

    Uncovered an antiviral/latency role: PRMT2 methylates HIV-1 Tat at R52 to retain it in nucleoli and exclude it from transcriptional condensates.

    Evidence cDNA screening, Co-IP, fractionation, phase-separation imaging, methylation assay and latency/patient CD4+ T cell models

    PMID:37949879

    Open questions at the time
    • host substrates governing latency reactivation untested
    • interplay with cellular transcription condensates not generalized
  16. 2023 Medium

    Extended the oncogenic H3R8me2a program to WNT5A/Wnt signaling in renal cell carcinoma.

    Evidence ChIP, overexpression/knockdown and xenograft

    PMID:37173306

    Open questions at the time
    • recruitment to the WNT5A promoter undefined
    • single lab
  17. 2024 Medium

    Placed PRMT2 downstream of HIF1α, showing its H3R8me2a activity drives a subset of hypoxia-induced genes and tumor migration.

    Evidence ChIP, HIF1α manipulation, PRMT2 inactivation, xenograft and clinical correlation

    PMID:38341123

    Open questions at the time
    • mechanism of HIF1α-driven PRMT2 activation not detailed here
    • single lab
  18. 2024 Medium

    Identified β-catenin methylation by PRMT2 driving its degradation and a β-catenin-GPX4 ferroptosis/microglial polarization axis in neuroinflammation.

    Evidence Co-IP, ubiquitination/degradation Western blots, siRNA and mouse behavioral assays

    PMID:38430350

    Open questions at the time
    • methylated arginine on β-catenin not mapped
    • link to E3 ligase activity undefined
  19. 2024 Low

    Proposed a cytoplasmic anti-inflammatory function via C15orf39-PRMT2 stabilization of IκBα to dampen NF-κB.

    Evidence Co-IP, IκBα Western blots, siRNA/overexpression and NF-κB reporter in microglia

    PMID:38892217

    Open questions at the time
    • enzymatic basis of IκBα stabilization not demonstrated
    • single Co-IP without reciprocal/in vitro validation
    • reconciliation with PRMT2's NF-κB-promoting roles unresolved
  20. 2025 Medium

    Showed PRMT2 activity is gated by CDK9 phosphorylation at Ser12, which drives condensate formation required for H3R8me2a under hypoxia.

    Evidence Phospho-site mutagenesis, CDK9 inhibitor TG02, condensate imaging, ChIP and xenograft

    PMID:40926175

    Open questions at the time
    • condensate composition not defined
    • single lab
  21. 2025 Medium

    Demonstrated citrullination of PRMT2 at R312 by PADI4 as a stabilizing modification enhancing its histone methylation and stem-like phenotypes.

    Evidence IP, protein stability Western blots, ChIP, R312 mutagenesis and PADI4 inhibitor GSK484 in OSCC

    PMID:40078091

    Open questions at the time
    • role of USP7 interaction in stabilization not fully resolved
    • single lab
  22. 2025 Medium

    Linked PRMT2 H3R8me2a to neuronal excitability in pain via FOXA2-dependent miR-323-3p induction and Kv2.1 suppression.

    Evidence Sequencing, ChIP, siRNA, patch-clamp and in vivo pain behavior

    PMID:40674210

    Open questions at the time
    • recruitment of PRMT2 to the miR-323-3p promoter undefined
    • single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PRMT2 is targeted to specific promoters and how the same H3R8me2a mark produces activating versus repressive transcriptional outcomes remains unresolved.
  • no defined reader of H3R8me2a
  • context-specific recruitment factors unknown
  • rules distinguishing activating from repressive deposition undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 5 GO:0140110 transcription regulator activity 4 GO:0042393 histone binding 3 GO:0098772 molecular function regulator activity 3
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0005730 nucleolus 1
Pathway
R-HSA-168256 Immune System 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 2 R-HSA-4839726 Chromatin organization 2 R-HSA-73894 DNA Repair 1
Partners
ARBRD4C15ORF39COBLE2F1ESR1RB1SAM68

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 PRMT2 (HRMT1L1) contains an N-terminal SH2 domain in addition to a methyltransferase core domain. The paralog HRMT1L2 (PRMT1) exhibited in vitro methyltransferase activity and complemented a yeast HMT1 mutant in vivo, establishing functional conservation; PRMT2 itself was identified as a putative arginine methyltransferase based on sequence homology. Sequence analysis, yeast complementation assay, in vitro methyltransferase assay (for HRMT1L2) Genomics Medium 9545638
2001 PRMT2 (HRMT1L1) interacts with the hnRNP E1B-AP5 via its SH3 domain (not SH2), co-localizes with E1B-AP5 in the nuclear fraction, and was identified as a candidate methyltransferase responsible for in vivo RGG-box methylation of E1B-AP5. Yeast two-hybrid screening, in situ immunofluorescence co-localization, domain-deletion analysis The Biochemical journal Medium 11513728
2006 PRMT2 directly binds RB through its AdoMet-binding domain (unlike PRMT1, PRMT3, PRMT4), forms a ternary complex with E2F1 in the presence of RB, represses E2F1 transcriptional activity in an RB-dependent manner, and PRMT2 knockout MEFs show increased E2F activity and accelerated S-phase entry. Co-immunoprecipitation, reporter assays, gene targeting (knockout MEFs), cell-cycle analysis, vascular injury model Experimental cell research High 16616919
2007 PRMT2 acts as a coactivator of the androgen receptor (AR), interacting with the AR C-terminal region (identified by yeast two-hybrid). PRMT2 coactivation is blocked by a methyltransferase competitive inhibitor, indicating catalytic activity is required. Under androgen-free conditions PRMT2 is cytoplasmic; androgen treatment triggers co-nuclear translocation of AR and PRMT2, whereas AR antagonist hydroxyflutamide causes AR but not PRMT2 nuclear translocation. Yeast two-hybrid, luciferase reporter assays, immunofluorescence, methyltransferase inhibitor treatment The Journal of steroid biochemistry and molecular biology Medium 17587566
2011 Three novel C-terminal splice variants of PRMT2 (PRMT2α, PRMT2β, PRMT2γ) have distinct subcellular localizations determined by their alternatively spliced C-termini. All variants bind ERα in vitro and in vivo via their N-terminal regions and enhance ERα-mediated transactivation. PRMT2 silencing enhances 17β-estradiol-induced proliferation by regulating E2F1 and E2F1-responsive genes. Confocal microscopy, GST pulldown, co-immunoprecipitation, luciferase reporter assays, siRNA knockdown The FEBS journal Medium 22093364
2011 PRMT2 regulates LPS-induced lung inflammatory responses; Prmt2 gene dosage controls airway hyperresponsiveness, neutrophil recruitment, and IL-6/TNF-α expression. Loss of PRMT2 impairs nuclear accumulation of NF-κB in stimulated macrophages. Mouse knockout/monosomy model, cytokine measurement, NF-κB nuclear fractionation Journal of immunology Medium 21957146
2015 PRMT2 is required for LXR-mediated ABCA1 expression and ABCA1-dependent cholesterol efflux in macrophages; Prmt2-/- bone marrow-derived macrophages show reduced ABCA1 expression and cholesterol efflux. PRMT2 expression is reduced under high-glucose conditions. Prmt2 knockout mouse BMDMs, cholesterol efflux assay, gene expression analysis PloS one Medium 26288135
2017 PRMT2 interacts with the splicing factor SAM68 via its SH3 domain, regulates SAM68 subcellular localization, and promotes an increase in the BCL-XL/BCL-XS ratio in TNF-α or LPS stimulated cells, demonstrating a role in alternative splicing of BCL-X. Proteomics (SH3 domain pulldown/MS), co-immunoprecipitation in cells, RT-PCR BCL-X isoform analysis Journal of biochemistry Medium 28057797
2018 PRMT2 is responsible for histone H3R8 asymmetric dimethylation (H3R8me2a). In glioblastoma, H3R8me2a enrichment at gene promoters/enhancers correlates with active histone marks and is required for oncogenic gene expression programs including cell cycle genes. Silencing or catalytic inactivation of PRMT2 inhibits GBM cell growth and glioblastoma stem cell self-renewal. ChIP-seq, siRNA/shRNA knockdown, catalytic mutant expression, in vitro and in vivo tumor models Nature communications High 30382083
2018 PRMT2 associates with the actin nucleator Cobl through its SH3 domain and methylates Cobl's C-terminal actin-nucleating domain. This methylation is required for Cobl's actin-binding activity and its role in dendritic arborization of neurons. PRMT2 phenocopies Cobl in gain- and loss-of-function assays, and both its catalytic domain and SH3 domain are required for its effects on dendritogenesis. Co-immunoprecipitation, in vitro reconstitution, cellular reconstitution, in vitro methylation assay, gain/loss-of-function in neurons, actin-binding assay Developmental cell High 29689199
2020 PRMT2 mediates H3R8me2a at the Bcl2 gene promoter, increasing chromatin accessibility for STAT3 and promoting Bcl2 expression. A catalytically inactive PRMT2 mutant or the type I PRMT inhibitor MS023 impairs these pro-tumorigenic functions in hepatocellular carcinoma cells. ChIP assay, catalytic mutant expression, PRMT inhibitor (MS023) treatment, apoptosis and proliferation assays Experimental cell research Medium 32574605
2021 PRMT2 methylates TLR4 at R731 and R812 (catalyzed via residues M115), and methylates IRF3 at R285. Arginine methylation of TLR4 at R812 mediates TLR4-IRF3 interaction; methylation of IRF3 at R285 induces IRF3 dimerization and nuclear translocation, promoting IFN-β production via TLR4/IRF3 signaling. PRMT2 mutants H112Q and M115I and TLR4 R812K mutant reduce IRF3 transcriptional activity. Co-immunoprecipitation, in vitro methylation assay, site-directed mutagenesis, nuclear fractionation, luciferase reporter assay, IFN-β measurement Molecular immunology Medium 34583098
2021 PRMT2 deposits repressive H3R8me2a at the SOCS3 promoter in colitis, inhibiting SOCS3 expression. Reduced SOCS3 prevents ubiquitination-mediated degradation of TRAF5, elevating TRAF5 and activating downstream NF-κB/MAPK signaling. PRMT2 overexpression aggravates and knockdown alleviates DSS-induced colitis. ChIP assay, lentiviral overexpression/knockdown in vivo, Western blot, DSS colitis mouse model British journal of pharmacology Medium 34599829
2022 PRMT2 arginine-methylates BRD4 at R179, R181, and R183 (with PRMT4). This methylation promotes BRD4 recruitment to acetylated histones/chromatin, controls a transcriptional program, and is induced by DNA damage to promote BRD4 chromatin binding for DNA repair. BRD4 arginine methylation deficiency suppresses tumor growth and sensitizes cells to BET inhibitors and DNA damaging agents. Co-immunoprecipitation, in vitro methylation assay, ChIP assay, site-directed mutagenesis, tumor xenograft, drug sensitivity assay Science advances High 36475791
2023 PRMT2 promotes HIV-1 latency by methylating HIV-1 Tat at R52, reinforcing Tat nucleolar sequestration by NPM1 and counteracting its incorporation into Super Elongation Complex (SEC) phase-separated condensates in the nucleoplasm, thereby inactivating Tat-dependent viral transcription. cDNA expression screening, co-immunoprecipitation, nucleolar/nuclear fractionation, phase-separation imaging, methylation assay, HIV latency cell line models, patient CD4+ T cell experiments Nature communications High 37949879
2023 PRMT2-mediated H3R8me2a is enriched at the WNT5A promoter, enhancing WNT5A transcriptional expression and activating Wnt signaling to drive RCC malignant progression. ChIP assay, overexpression/knockdown in cell lines, in vivo xenograft Cell death & disease Medium 37173306
2024 PRMT2 is activated by HIF1α under hypoxic conditions and its H3R8me2a activity is required for transcriptional activation of a subset of hypoxia-induced genes, driving glioblastoma cell migration and tumor progression. ChIP assay, HIF1α knockdown/overexpression, PRMT2 inactivation, mouse xenograft, clinical specimen correlation Cellular signalling Medium 38341123
2024 PRMT2 promotes arginine methylation of β-catenin, inducing its proteasomal degradation, which transcriptionally inhibits GPX4 expression. This leads to ferroptosis and M1 polarization of microglia via the β-catenin-GPX4 axis in LPS-induced neuroinflammation and depression. Co-immunoprecipitation, Western blot (ubiquitination/degradation), siRNA knockdown, behavioral assays in mice Molecular neurobiology Medium 38430350
2024 C15orf39 (PRMT2 IP) interacts with cytoplasmic PRMT2 and together they stabilize IκBα to suppress NF-κB signaling and reduce IL-6/TNF-α transcription in microglia under steady-state conditions. Co-immunoprecipitation, Western blot (IκBα levels), siRNA/overexpression, NF-κB reporter assay International journal of molecular sciences Low 38892217
2025 Hypoxia triggers phosphorylation of PRMT2 at Serine 12 (within its N-terminal intrinsically disordered region) by CDK9, driving PRMT2 condensation into transcriptional condensates, which is required for its H3R8me2a activity and hypoxia-inducible gene expression in glioblastoma. Phosphorylation site mutagenesis, CDK9 inhibitor (TG02), condensate imaging, ChIP for H3R8me2a, in vivo xenograft Science China. Life sciences Medium 40926175
2025 PADI4 citrullinates PRMT2 at R312, which stabilizes PRMT2 protein expression and enhances its function in promoting H3R8 histone arginine methylation-dependent transcription of ID1 and ID2. Citrullination also affects PRMT2 interaction with the deubiquitinase USP7. R312 mutation or GSK484 PADI4 inhibition reduces PRMT2 activity, stem-like properties, and cisplatin resistance in OSCC. Immunoprecipitation, Western blot (protein stability), ChIP, site-directed mutagenesis (R312), PADI4 inhibitor (GSK484), cancer stem cell assays Clinical and translational medicine Medium 40078091
2025 In trigeminal neuropathic pain, nerve injury upregulates PRMT2 in sensory neurons, which promotes H3R8 asymmetric dimethylation at the miR-323-3p promoter, facilitating FOXA2 binding and upregulating miR-323-3p expression. Increased miR-323-3p reduces Kv2.1 potassium channel expression and currents, causing TG neuronal hyperexcitability. High-throughput sequencing, ChIP assay, siRNA knockdown, patch-clamp electrophysiology, in vivo pain behavioral assays Cell reports Medium 40674210

Source papers

Stage 0 corpus · 33 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 152 9545638
2018 PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nature communications 96 30382083
2006 The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Experimental cell research 72 16616919
2007 PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor. The Journal of steroid biochemistry and molecular biology 71 17587566
2001 Heterogeneous nuclear ribonucleoprotein E1B-AP5 is methylated in its Arg-Gly-Gly (RGG) box and interacts with human arginine methyltransferase HRMT1L1. The Biochemical journal 67 11513728
2011 Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. The FEBS journal 58 22093364
2014 PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Molecular endocrinology (Baltimore, Md.) 47 24911119
2020 PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Experimental cell research 42 32574605
2022 Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair. Science advances 40 36475791
2018 Arginine Methylation by PRMT2 Controls the Functions of the Actin Nucleator Cobl. Developmental cell 40 29689199
2021 Structure, Activity and Function of the PRMT2 Protein Arginine Methyltransferase. Life (Basel, Switzerland) 34 34833139
2015 LXR-Mediated ABCA1 Expression and Function Are Modulated by High Glucose and PRMT2. PloS one 34 26288135
2011 Identification and expression analysis of a novel transcript of the human PRMT2 gene resulted from alternative polyadenylation in breast cancer. Gene 30 21820040
2017 PRMT2 interacts with splicing factors and regulates the alternative splicing of BCL-X. Journal of biochemistry 28 28057797
2023 PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression. Cell death & disease 26 37173306
2010 The telomeric part of the human chromosome 21 from Cstb to Prmt2 is not necessary for the locomotor and short-term memory deficits observed in the Tc1 mouse model of Down syndrome. Behavioural brain research 25 21047530
2011 Prmt2 regulates the lipopolysaccharide-induced responses in lungs and macrophages. Journal of immunology (Baltimore, Md. : 1950) 23 21957146
2024 Arginine Methylation of β-Catenin Induced by PRMT2 Aggravates LPS-Induced Cognitive Dysfunction and Depression-Like Behaviors by Promoting Ferroptosis. Molecular neurobiology 22 38430350
2021 Protein arginine methyltransferase 2 (PRMT2) promotes dextran sulfate sodium-induced colitis by inhibiting the SOCS3 promoter via histone H3R8 asymmetric dimethylation. British journal of pharmacology 20 34599829
2021 Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway. Molecular immunology 18 34583098
2023 PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex. Nature communications 13 37949879
2022 Loss of PRMT2 in myeloid cells in normoglycemic mice phenocopies impaired regression of atherosclerosis in diabetic mice. Scientific reports 13 35835907
2017 PRMT2β, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells. Oncology reports 12 28677794
2024 PRMT2 silencing regulates macrophage polarization through activation of STAT1 or inhibition of STAT6. BMC immunology 10 38172698
2020 PRMT2 inhibits the formation of foam cell induced by ox-LDL in RAW 264.7 macrophage involving ABCA1 mediated cholesterol efflux. Biochemical and biophysical research communications 10 31980179
2024 Hypoxia-inducible PRMT2 addiction in glioblastomas. Cellular signalling 7 38341123
2023 Arginine methyltransferases PRMT2 and PRMT3 are essential for biosynthesis of plant-polysaccharide-degrading enzymes in Penicillium oxalicum. PLoS genetics 7 37523410
2025 PADI4 facilitates stem-like properties and cisplatin resistance through upregulating PRMT2/IDs family in oesophageal squamous cell carcinoma. Clinical and translational medicine 6 40078091
2025 PRMT2 promotes tumorigenic phenotypes through the Wnt signaling pathway and drives immune suppression in Colorectal cancer. Cancer letters 4 40769293
2025 Transcriptional condensates enrich phosphorylated PRMT2 to stimulate H3R8me2a deposition and hypoxic response in glioblastoma. Science China. Life sciences 4 40926175
2014 Identification of splice variants, expression analysis and single nucleotide polymorphisms of the PRMT2 gene in dairy cattle. Gene 4 24502989
2024 Human C15orf39 Inhibits Inflammatory Response via PRMT2 in Human Microglial HMC3 Cell Line. International journal of molecular sciences 3 38892217
2025 PRMT2-mediated upregulation of miR-323-3p in sensory neurons promotes trigeminal neuropathic pain by targeting Kv2.1 channels. Cell reports 1 40674210

Missed literature

Know a paper Affinage missed for PRMT2? Flag it for the maintainers and the community.

No submissions yet.